Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$490.9 million.
- Viridian Therapeutics, Inc.\DE's Enterprise Value rose 3482.81% to -$490.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$490.9 million, marking a year-over-year increase of 3482.81%. This contributed to the annual value of -$717.6 million for FY2024, which is 5032.03% down from last year.
- Viridian Therapeutics, Inc.\DE's Enterprise Value amounted to -$490.9 million in Q3 2025, which was up 3482.81% from -$563.4 million recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's 5-year Enterprise Value high stood at -$109.3 million for Q2 2021, and its period low was -$753.2 million during Q3 2024.
- Moreover, its 5-year median value for Enterprise Value was -$424.6 million (2022), whereas its average is -$403.9 million.
- As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Enterprise Value tumbled by 61083.48% in 2021, and later skyrocketed by 3482.81% in 2025.
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Enterprise Value stood at -$197.0 million in 2021, then crashed by 115.55% to -$424.6 million in 2022, then dropped by 12.44% to -$477.4 million in 2023, then tumbled by 50.32% to -$717.6 million in 2024, then soared by 31.59% to -$490.9 million in 2025.
- Its Enterprise Value was -$490.9 million in Q3 2025, compared to -$563.4 million in Q2 2025 and -$636.6 million in Q1 2025.